A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Philippe Georges Aftimos, Mafalda Oliveira, Kevin Punie, Valentina Boni, Erika P. Hamilton, Ayca Gucalp, Payal D Shah, Maria J. de Miguel, Priyanka Sharma, Lisa Bauman, Eric Campeau, Sarah Attwell, Margo Snyder, Karen Norek, Emily Johnson, Michael H. Silverman, Sanjay Lakhotia, Susan M. Domchek, Jennifer Keating Litton, Mark E. Robson
Institutions: Université Libre de Bruxelles, Institut Jules Bordet, Vall d'Hebron Institute of Oncology, Universitair Ziekenhuis Leuven, Hospital Universitario HM Sanchinarro, Sarah Cannon, Tennessee Oncology, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, University of Kansas Medical Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4282029268